HemoShear Therapeutics Overview
- Year Founded
-
2008
- Status
-
Private
- Employees
-
62
- Latest Deal Type
-
Debt
- Latest Deal Amount
-
$3.5M
- Investors
-
7
HemoShear Therapeutics General Information
Description
Developer of novel drug treatments designed to improve the quality of life of patients with rare metabolic diseases. The company's treatments improve the lives of people born with rare metabolic defects who are unable to sustain basic biochemical processes necessary for life, enabling healthcare organizations to accelerate drug discovery and development programs in liver diseases, gout, and metabolic disorders.
Contact Information
Website
www.hemoshear.comCorporate Office
- 501 Locust Avenue
- Suite 301
- Charlottesville, VA 22902
- United States
Corporate Office
- 501 Locust Avenue
- Suite 301
- Charlottesville, VA 22902
- United States
HemoShear Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 16. Debt - General | 14-Nov-2023 | $3.5M | Completed | Generating Revenue | ||
| 15. Later Stage VC (Series A) | 18-Feb-2021 | Completed | Generating Revenue | |||
| 14. Debt - PPP | 08-Apr-2020 | Completed | Generating Revenue | |||
| 13. Later Stage VC | 20-Feb-2020 | Completed | Generating Revenue | |||
| 12. Later Stage VC | 15-May-2017 | Completed | Generating Revenue | |||
| 11. Later Stage VC | 30-Mar-2017 | Completed | Generating Revenue | |||
| 10. Later Stage VC (Series C1) | 07-May-2014 | Completed | Generating Revenue | |||
| 9. Grant | 01-Jan-2013 | Completed | Startup | |||
| 8. Later Stage VC (Series C) | 24-Oct-2012 | $4M | $10.2M | Completed | Startup | |
| 7. Grant | 01-Jan-2011 | $4.48M | $6.22M | Completed | Startup |
HemoShear Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
HemoShear Therapeutics Comparisons
Industry
Financing
Details
HemoShear Therapeutics Competitors (53)
One of HemoShear Therapeutics’s 53 competitors is NGM Biopharmaceuticals, a Private Equity-Backed company based in South San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| NGM Biopharmaceuticals | Private Equity-Backed | South San Francisco, CA | ||||
| Regenerx | Formerly VC-backed | Rockville, MD | ||||
| WaVe Life Sciences | Formerly VC-backed | Cambridge, MA | ||||
| etherna | Formerly VC-backed | Niel, Belgium | ||||
| Adimab | Venture Capital-Backed | Lebanon, NH |
HemoShear Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
HemoShear Therapeutics Patents
HemoShear Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2024163962-A1 | 3-((1,1-dioxido-2,3,4,5-tetrahydrobenzo[f][1,2,5]thiadiazepin-8-yl)oxy)-2-fluoroacrylic acid derivatives as sodium taurocholate co-transporting polypeptide (ntcp) inhibitors for the treatment of cholestasis | Inactive | 03-Feb-2023 | ||
| US-20240254485-A1 | Sirnas targeting slc10a1 transcripts, compositions and uses thereof | Pending | 13-Jan-2023 | ||
| WO-2024151942-A2 | Sirnas targeting slc10a1 transcripts, compositions and uses thereof | Inactive | 13-Jan-2023 | ||
| WO-2024151942-A3 | Sirnas targeting slc10a1 transcripts, compositions and uses thereof | Inactive | 13-Jan-2023 | ||
| EP-4416287-A1 | Compositions and methods of treating diseases associated with bile acid transporter | Inactive | 14-Oct-2021 | C12N15/1138 |
HemoShear Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
HemoShear Therapeutics Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Adage Capital Management | Hedge Fund | Minority | ||
| Janus Henderson Investors | Asset Manager | Minority | ||
| Montanova Capital | Hedge Fund | Minority | ||
| Angel (individual) | Minority | |||
| Virginia Capital Partners | Venture Capital | Minority |
HemoShear Therapeutics FAQs
-
When was HemoShear Therapeutics founded?
HemoShear Therapeutics was founded in 2008.
-
Where is HemoShear Therapeutics headquartered?
HemoShear Therapeutics is headquartered in Charlottesville, VA.
-
What is the size of HemoShear Therapeutics?
HemoShear Therapeutics has 62 total employees.
-
What industry is HemoShear Therapeutics in?
HemoShear Therapeutics’s primary industry is Drug Discovery.
-
Is HemoShear Therapeutics a private or public company?
HemoShear Therapeutics is a Private company.
-
What is HemoShear Therapeutics’s current revenue?
The current revenue for HemoShear Therapeutics is .
-
How much funding has HemoShear Therapeutics raised over time?
HemoShear Therapeutics has raised $71.4M.
-
Who are HemoShear Therapeutics’s investors?
Adage Capital Management, Janus Henderson Investors, Montanova Capital, , and Virginia Capital Partners are 5 of 7 investors who have invested in HemoShear Therapeutics.
-
Who are HemoShear Therapeutics’s competitors?
NGM Biopharmaceuticals, Regenerx, WaVe Life Sciences, etherna, and Adimab are some of the 53 competitors of HemoShear Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
